Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 92 PS3-25-07 | DOI: 10.1530/endoabs.92.PS3-25-07

1Azienda Ospedaliero-Universitaria Pisana, Department of Emergency Medicine, Pisa, Italy; 2University Cardiology Department, Irccs Policlinico San Donato, Milano, Italy; 3University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy; 4University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area, Pisa, Italy; 5University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy

The risk of thyroid dysfunction induced by Interferon (IFN)-β1b therapy, in particular in patients having preexisting thyroid autoimmune disorders (AITD), is well known. We report a case of a 60-year-old female, with a 15-year history of euthyroid autoimmune thyroiditis and a 3-year history of Multiple Sclerosis (MS), in care for the evaluation of hyperthyroidism. The patient started a specific immunomodulant IFN-β1a therapy (30 μg/week) twenty months before the first visit, during which complained tachycardia, weight loss, blurry vision with swollen eyes and excessive lacrimation. The thyroid hormone profile showed hyperthyroidism with positive TSH-receptor-autoantibodies. An orbit Magnetic Resonance Imaging (MRI) was performed, revealing bilaterally mild enlargement of the extraocular muscles and supporting the suspect of Graves’ ophthalmopathy (GO). To our knowledge, this is the first report of Graves’ disease (GD) and GO associated with IFN-β1a treatment in a patient with MS. This case report could open new interesting insights behind the immunopathogenesis of GD.

Keywords: Graves’ disease; Graves’ ophthalmopathy; thyroid dysfunction; Interferon (IFN)-β1b therapy

Volume 92

45th Annual Meeting of the European Thyroid Association (ETA) 2023

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.